With the goal of targeting mutant KRAS signaling and identifying novel partners of mutant RAS-mediated oncogenesis, we recently probed a panel of human cancer cell lines for protein partners of RAS and identified an interaction between KRAS and Argonaute 2 (AGO2) (9, 10), a key member of the RNA-induced silencing complex (RISC). The gene discussed is AGO2; the disease is cancer.